Kim Seth
Corporate Officer/Principal at REPARE THERAPEUTICS INC.
Net worth: 79 953 $ as of 30/04/2024
Kim Seth active positions
Companies | Position | Start | End |
---|---|---|---|
REPARE THERAPEUTICS INC. | Corporate Officer/Principal | 01/06/2017 | - |
Career history of Kim Seth
Former positions of Kim Seth
Companies | Position | Start | End |
---|---|---|---|
Resilience Therapeutics, Inc.
Resilience Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Resilience Therapeutics, Inc. operates as a pharmaceuticals store. The company was founded by Retsina Meyer, Brad Geddes and Veronica Weiner and is headquartered in Duxbury, MA. | Director/Board Member | 01/07/2015 | 01/05/2017 |
Chief Operating Officer | 01/07/2015 | 01/05/2017 | |
Founder | 01/07/2015 | 01/05/2017 | |
EPIRUS BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2014 | 01/01/2015 |
PFIZER, INC. | Corporate Officer/Principal | 01/01/2011 | 01/02/2014 |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | 01/05/2006 | 01/06/2010 |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 07/05/2014 | - |
Training of Kim Seth
Harvard University | Doctorate Degree |
Harvard College | Undergraduate Degree |
Statistics
International
United States | 8 |
Canada | 2 |
Operational
Corporate Officer/Principal | 5 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
PFIZER, INC. | Health Technology |
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
REPARE THERAPEUTICS INC. | Health Technology |
Private companies | 3 |
---|---|
Resilience Therapeutics, Inc.
Resilience Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Resilience Therapeutics, Inc. operates as a pharmaceuticals store. The company was founded by Retsina Meyer, Brad Geddes and Veronica Weiner and is headquartered in Duxbury, MA. | Health Technology |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kim Seth
- Experience